Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive impairment due to neuronal death. Although the lost of cognitive function is the main problem for AD subjects, death occurs due to secondary issues such as concomitant infections, respiratory complications or multi-organ failure. Current drugs used in AD are acetylcholinesterase inhibitors and antagonists of the N-methyl-D-aspartate receptor. These drugs may only slightly improve cognitive functions but have only very limited impact on the clinical course of the disease. Over the last 5 years, new targets were identified and innovative drugs against AD have been designed and developed. Worthy of mention are β-secretase inhibitors, monoclonal antibodies against amyloid-β-peptide and tau inhibitors. However, although promising beneficial effects were highlighted in the data from preclinical studies, only few of these new drugs improved cognitive functions for a significant time frame in AD subjects. Controversial is the therapeutic effect on AD obtained through the manipulation of the nitric oxide synthase/nitric oxide system since the potential toxic effects on brain function could overcome the beneficial effects. The aim of this review is to analyze from a pharmacologic point of view both old and new drugs developed for the treatment of AD. In addition, the risk/benefit ratio related to the modulation of the nitric oxide synthase/nitric oxide system in AD brain will be analyzed.
Keywords: Acetylcholinesterase inhibitors, Alzhiemers disease, Amyloid β peptide, Memantine, Nitric oxide, Secretases, Tau Protein, APOE, CREB, Latrepirdine, EVT 101
CNS & Neurological Disorders - Drug Targets
Title: Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
Volume: 10 Issue: 7
Author(s): Raffaella Siciliano, Eugenio Barone, Vittorio Calabrese, Vincenzo Rispoli, D. Allan Butterfield and Cesare Mancuso
Affiliation:
Keywords: Acetylcholinesterase inhibitors, Alzhiemers disease, Amyloid β peptide, Memantine, Nitric oxide, Secretases, Tau Protein, APOE, CREB, Latrepirdine, EVT 101
Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive impairment due to neuronal death. Although the lost of cognitive function is the main problem for AD subjects, death occurs due to secondary issues such as concomitant infections, respiratory complications or multi-organ failure. Current drugs used in AD are acetylcholinesterase inhibitors and antagonists of the N-methyl-D-aspartate receptor. These drugs may only slightly improve cognitive functions but have only very limited impact on the clinical course of the disease. Over the last 5 years, new targets were identified and innovative drugs against AD have been designed and developed. Worthy of mention are β-secretase inhibitors, monoclonal antibodies against amyloid-β-peptide and tau inhibitors. However, although promising beneficial effects were highlighted in the data from preclinical studies, only few of these new drugs improved cognitive functions for a significant time frame in AD subjects. Controversial is the therapeutic effect on AD obtained through the manipulation of the nitric oxide synthase/nitric oxide system since the potential toxic effects on brain function could overcome the beneficial effects. The aim of this review is to analyze from a pharmacologic point of view both old and new drugs developed for the treatment of AD. In addition, the risk/benefit ratio related to the modulation of the nitric oxide synthase/nitric oxide system in AD brain will be analyzed.
Export Options
About this article
Cite this article as:
Siciliano Raffaella, Barone Eugenio, Calabrese Vittorio, Rispoli Vincenzo, Allan Butterfield D. and Mancuso Cesare, Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge, CNS & Neurological Disorders - Drug Targets 2011; 10 (7) . https://dx.doi.org/10.2174/187152711798072356
DOI https://dx.doi.org/10.2174/187152711798072356 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders
Current Enzyme Inhibition Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Polyglutamine and Neurodegeneration: Structural Aspects
Protein & Peptide Letters LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals
Current Neuropharmacology Drug Delivery Technologies and Stem Cells for Tissue Repair and Regeneration
Current Pharmaceutical Biotechnology Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Current Alzheimer Research Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate
Current Alzheimer Research Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Current Alzheimer Research Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Plasma Metabolic Profiling of Mild Cognitive Impairment and Alzheimer's Disease Using Liquid Chromatography/Mass Spectrometry
Central Nervous System Agents in Medicinal Chemistry Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders
Current Molecular Medicine Meet Our Editorial Board Member
Current Aging Science Aqueous Extract of <i>Cola nitida</i> and <i>Garcinia kola</i> Synergistically Enhances Hippocampal-hypothalamic Glutamate and Na+ /K+ -ATPase Activity in Male Wistar Rats
Current Drug Discovery Technologies Phenolic Compounds from Plants as Nitric Oxide Production Inhibitors
Current Medicinal Chemistry RNA Interference as a Tool for Alzheimers Disease Therapy
Mini-Reviews in Medicinal Chemistry Long non-coding RNAs in Alzheimer’s disease
Current Topics in Medicinal Chemistry Restriction Factors Against Recombinant Adeno-associated Virus Vectormediated Gene Transfer in Dystrophin-deficient Muscles
Current Gene Therapy Mitochondrially-Targeted Therapeutic Strategies for Alzheimer’s Disease
Current Alzheimer Research